News for Adicet Bio, Inc. (0HX7.L)

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. ( HOWL), an innovative biopharmaceutical company pioneering the development of

**media[548365]**

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Inc. (ACET) experienced a significant stock price drop of 5.43%, trading at $0.965 per share with a volume of 279,487 shares and a turnover rate of 0

Adicet Bio Inc. (ACET) experienced a significant stock movement, dropping 5.45% to $1.04 per share. The trading volume reached 409,983 shares with a turnover ra

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio begins trial for innovative cancer therapy

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

FDA greenlights Adicet Bio's trial expansion for autoimmune diseases

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<

The marginal zone lymphoma pipeline possesses potential drugs in mid-stage developments to be launched in the near future. The total marginal zone lymphoma...

On Wednesday, 311 stocks hit new 52-week lows.

The DLBCL market has a diverse pipeline, with the emergence of novel classes such as bi-specific antibodies, cancer vaccines, and allogeneic CAR-Ts in the...

Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV® and RonapreveTM, revenues increased 14%Full year 2022 revenues decreased 24% to $12.17... | February 3, 2023

Marginal Zone Lymphoma Pipeline constitutes 40+ key companies continuously working towards developing 50+ Marginal Zone Lymphoma treatment therapies,...

SAN DIEGO & VANCOUVER, British Columbia — Tentarix Biotherapeutics LP, a biotechnology company developing first-in-class targeted, conditional antibody-based…